Genomtec (FRA:4VI) Total Equity: €1.62 Mil (As of Mar. 2026)


FRA:4VI Genomtec SA FRA:4VI
32 GF Score
Price €0.98
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Genomtec Total Equity?

Genomtec FRA:4VI -0.31% 32 Total Equity is €1.62 Mil as of Mar. 2026. GuruFocus rates FRA:4VI with a GF Score™ of 32/100 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Genomtec's total equity for the quarter that ended in Mar. 2026 was €1.62 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Genomtec Total Equity Historical Data

* Premium members only.

The historical data trend for Genomtec's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomtec Total Equity Chart

Genomtec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 0.17 1.13 1.92 1.76 2.13

Genomtec Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.51 2.99 2.39 2.13 1.62
FRA:4VI
32GF Score
Genomtec SA FRA:4VI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomtec Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Genomtec's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3.553-1.421
=2.13

Genomtec's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3.014-1.39
=1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1.62 Mil mean?
Genomtec (FRA:4VI) has a Total Equity of €1.62 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Genomtec and its competitors.
Is Genomtec's Total Equity too high?
Genomtec's current Total Equity is €1.62 Mil. Overall, Genomtec has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomtec's Total Equity compare to ABT and SYK?
Genomtec's Total Equity of €1.62 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Genomtec and its competitors. Genomtec's current Total Equity is €1.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomtec stock overvalued right now?
Based on GuruFocus' analysis, Genomtec (FRA:4VI) is currently considered Significantly Overvalued. The current Total Equity is €1.62 Mil. Genomtec's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Genomtec (FRA:4VI), the current Total Equity is €1.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genomtec Business Description

Other Exchanges GMT:Poland
Address ul. Stablowicka 147, PORT Building 2, Wroclaw, POL, 54-066
Genomtec SA is an technology company which works in the area of ?? molecular diagnostics. It is a manufacturer of mobile molecular analyzers. The device are designed to identify pathogens including viruses, bacteria, and fungi by amplifying and detecting specific DNA and RNA fragments.
32GF Score

Get the complete analysis for FRA:4VI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price